[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SI9110925A - Uporaba magnezijevega piridoksal-5'-fosfat-glutaminata za pripravo zdravil za preventivo bolezni, ki nastanejo zaradi poškodb ožilja - Google Patents

Uporaba magnezijevega piridoksal-5'-fosfat-glutaminata za pripravo zdravil za preventivo bolezni, ki nastanejo zaradi poškodb ožilja Download PDF

Info

Publication number
SI9110925A
SI9110925A SI9110925A SI9110925A SI9110925A SI 9110925 A SI9110925 A SI 9110925A SI 9110925 A SI9110925 A SI 9110925A SI 9110925 A SI9110925 A SI 9110925A SI 9110925 A SI9110925 A SI 9110925A
Authority
SI
Slovenia
Prior art keywords
phosphate
ldl
cholesterol
glutaminate
mppg
Prior art date
Application number
SI9110925A
Other languages
English (en)
Slovenian (sl)
Inventor
Werner Schneider
Britta Meyer
Erich Elstner
Original Assignee
Steigerwald Arzneimittelwerk Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Steigerwald Arzneimittelwerk Gmbh filed Critical Steigerwald Arzneimittelwerk Gmbh
Publication of SI9110925A publication Critical patent/SI9110925A/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI9110925A 1990-05-25 1991-05-23 Uporaba magnezijevega piridoksal-5'-fosfat-glutaminata za pripravo zdravil za preventivo bolezni, ki nastanejo zaradi poškodb ožilja SI9110925A (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4016963A DE4016963A1 (de) 1990-05-25 1990-05-25 Verwendung von magnesium-pyridoxal-5'-phosphat-glutaminat zur verhinderung von erkrankungen, die sich infolge von gefaessschaeden ergeben
YU92591 1991-05-23

Publications (1)

Publication Number Publication Date
SI9110925A true SI9110925A (sl) 1998-06-30

Family

ID=6407228

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9110925A SI9110925A (sl) 1990-05-25 1991-05-23 Uporaba magnezijevega piridoksal-5'-fosfat-glutaminata za pripravo zdravil za preventivo bolezni, ki nastanejo zaradi poškodb ožilja

Country Status (28)

Country Link
US (1) US5372999A (de)
EP (1) EP0458287B1 (de)
JP (1) JPH07119174B2 (de)
KR (1) KR970005180B1 (de)
CN (1) CN1050750C (de)
AT (1) ATE142884T1 (de)
AU (1) AU651108B2 (de)
CA (1) CA2043228C (de)
CZ (1) CZ280683B6 (de)
DE (2) DE4016963A1 (de)
DK (1) DK0458287T3 (de)
EG (1) EG19730A (de)
ES (1) ES2091262T3 (de)
GR (1) GR3021077T3 (de)
HR (1) HRP931445B1 (de)
HU (1) HU219223B (de)
IE (1) IE76728B1 (de)
IL (1) IL98156A (de)
IN (1) IN173057B (de)
LT (1) LT3335B (de)
LV (1) LV10046B (de)
MD (1) MD306C2 (de)
MX (1) MX171883B (de)
RU (1) RU2041713C1 (de)
SI (1) SI9110925A (de)
SK (1) SK278896B6 (de)
UA (1) UA26973A1 (de)
ZA (1) ZA913692B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19527820A1 (de) * 1995-07-28 1997-01-30 Leniger Follert Elfriede Prof Arzneimittel zur Behandlung von Ulcera, insbesondere bei arteriellen und venösen Durchblutungsstörungen der Extremitäten, bei chronisch venöser Insuffizienz und Lymphödem
DE19532625C2 (de) * 1995-09-04 2000-04-20 Steigerwald Arzneimittelwerk Verfahren zur Herstellung von Magnesium-pyridoxal-5'-phosphat-glutamat und dabei erhaltene Zwischenprodukte
US6043259A (en) * 1998-07-09 2000-03-28 Medicure Inc. Treatment of cardiovascular and related pathologies
DK1169322T3 (da) 1999-03-08 2006-03-06 Medicure Inc Pyridoxalanaloger til behandling af lidelser foranlediget af vitamin B6-mangel
US6489345B1 (en) 1999-07-13 2002-12-03 Medicure, Inc. Treatment of diabetes and related pathologies
US6677356B1 (en) * 1999-08-24 2004-01-13 Medicure International Inc. Treatment of cardiovascular and related pathologies
ES2240419T3 (es) 2000-02-29 2005-10-16 Medicure International Inc. Fosfonatos protectores del corazon.
US7442689B2 (en) * 2000-02-29 2008-10-28 Medicure International Inc. Cardioprotective phosphonates and malonates
WO2001072309A2 (en) 2000-03-28 2001-10-04 Medicure International Inc. Treatment of cerebrovascular disease
US6897228B2 (en) 2000-07-07 2005-05-24 Medicure International Inc. Pyridoxine and pyridoxal analogues: new uses
ATE364595T1 (de) 2000-07-07 2007-07-15 Medicure Int Inc Pyridoxin- und pyridoxalanaloga als cardiovasculäre therapeutika
US6548519B1 (en) 2001-07-06 2003-04-15 Medicure International Inc. Pyridoxine and pyridoxal analogues: novel uses
US20070060549A1 (en) * 2004-08-10 2007-03-15 Friesen Albert D Combination therapies employing ace inhibitors and uses thereof for the treatment of diabetic disorders
US7459468B2 (en) 2004-10-28 2008-12-02 Medicure International, Inc. Aryl sulfonic pyridoxines as antiplatelet agents
WO2006050598A1 (en) 2004-10-28 2006-05-18 Medicure International Inc. Dual antiplatelet/anticoagulant pyridoxine analogs
JP2010535013A (ja) 2007-03-14 2010-11-18 シエラ モレキュラー コーポレイション 細胞および／または高分子の保存および／または安定化のための組成物、システムおよび方法
RU2484843C1 (ru) * 2012-04-03 2013-06-20 Алексей Кириллович Пехтерев Лекарственный сбор растений для лечения сердечно-сосудистых заболеваний

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE246172C (de)
DE2461742C2 (de) * 1974-12-28 1983-01-27 Steigerwald Arzneimittelwerk Gmbh, 6100 Darmstadt Pyridoxin-5'-phosphorsäureester-Derivate sowie deren Herstellung und diese Verbindungen enthaltende Arzneimittel
DE3807895A1 (de) * 1988-03-10 1989-09-21 Knoll Ag Erzeugnisse, enthaltend einen calciumantagonisten und einen lipidsenker

Also Published As

Publication number Publication date
CA2043228C (en) 1998-07-14
ZA913692B (en) 1992-02-26
IL98156A0 (en) 1992-06-21
AU7730191A (en) 1991-11-28
LT3335B (en) 1995-07-25
ATE142884T1 (de) 1996-10-15
LTIP580A (en) 1994-12-27
LV10046B (en) 1995-02-20
CA2043228A1 (en) 1991-11-26
KR910019616A (ko) 1991-12-19
UA26973A1 (uk) 2000-02-28
HUT58204A (en) 1992-02-28
LV10046A (lv) 1994-05-10
DE4016963A1 (de) 1991-11-28
GR3021077T3 (en) 1996-12-31
AU651108B2 (en) 1994-07-14
RU2041713C1 (ru) 1995-08-20
MD306B1 (ro) 1995-10-31
SK278896B6 (sk) 1998-04-08
US5372999A (en) 1994-12-13
DE69122170T2 (de) 1997-02-20
EP0458287A2 (de) 1991-11-27
HRP931445B1 (en) 2000-04-30
CZ280683B6 (cs) 1996-04-17
CS156391A3 (en) 1992-02-19
CN1057391A (zh) 1992-01-01
CN1050750C (zh) 2000-03-29
DE69122170D1 (de) 1996-10-24
IL98156A (en) 1996-06-18
HRP931445A2 (en) 1996-02-29
KR970005180B1 (ko) 1997-04-14
ES2091262T3 (es) 1996-11-01
MX171883B (es) 1993-11-22
IE76728B1 (en) 1997-11-05
HU911756D0 (en) 1991-12-30
EG19730A (en) 1996-01-31
EP0458287B1 (de) 1996-09-18
IE911783A1 (en) 1991-12-04
DE4016963C2 (de) 1992-04-30
EP0458287A3 (en) 1992-04-08
IN173057B (de) 1994-02-05
JPH04235130A (ja) 1992-08-24
JPH07119174B2 (ja) 1995-12-20
HU219223B (en) 2001-03-28
DK0458287T3 (da) 1996-10-07
MD306C2 (ro) 1996-02-29

Similar Documents

Publication Publication Date Title
SI9110925A (sl) Uporaba magnezijevega piridoksal-5'-fosfat-glutaminata za pripravo zdravil za preventivo bolezni, ki nastanejo zaradi poškodb ožilja
Overduin et al. Dietary galacto-oligosaccharides and calcium: effects on energy intake, fat-pad weight and satiety-related, gastrointestinal hormones in rats
de Sotillo et al. Chlorogenic acid modifies plasma and liver concentrations of: cholesterol, triacylglycerol, and minerals in (fa/fa) Zucker rats
Gürbüz et al. Evaluation of the anti-ulcerogenic effect of sesquiterpene lactones from Centaurea solstitialis L. ssp. solstitialis by using various in vivo and biochemical techniques
Sanderson et al. Lipids and Dupuytren's disease
Ramírez-Tortosa et al. Olive oil-and fish oil-enriched diets modify plasma lipids and susceptibility of LDL to oxidative modification in free-living male patients with peripheral vascular disease: the Spanish Nutrition Study
Hawkey et al. Separation of the impairment of haemostasis by aspirin from mucosal injury in the human stomach
Steiner et al. A comparative review of the adverse effects of treatments for hyperlipidaemia
JP2010502776A (ja) 小麦胚芽油濃縮物、その製造方法、小麦胚芽油の製造方法、ならびにそれに基づく、性機能障害を回復するための医療用および予防用組成物
Kagawa et al. Garlic extract inhibits the enhanced peroxidation and production of lipids in carbon tetrachloride-induced liver injury
Sarica et al. Evaluation of urinary oxalate levels in patients receiving gastrointestinal lipase inhibitor
JP5186679B2 (ja) 血管病予防に効果を有する食品組成物
Borum et al. Fecal bile acid excretion and composition in response to changes in dietary wheat bran, fat and calcium in the rat
Chin-Dusting et al. Lipids and atherosclerosis: clinical management of hypercholesterolaemia
JP5504405B2 (ja) 血管病予防に効果を有する食品組成物
Kuklinski et al. Interaction between vitamin E and selenium under clinical conditions
Caird Metabolism of digoxin in relation to therapy in the elderly
Omura et al. Factors in the prevention of cardio-vascular diseases--Part 1: 96 cardio-vascular risk factors, with special emphasis on the prevention and treatment of hypertension, controllable dietary risk factors, and recommended US dietary goals
Davis et al. The effect of plasma free fatty acids and long-chain triglycerides on glucose metabolism in uncomplicated falciparum malaria
WO2002076505A1 (fr) Remedes pour trouble de stress post-traumatique
Al-Saady The role of omega-3 fatty acids
JPS61246146A (ja) エイコサペンタエノイルグリセライド含有脂質低下剤
Eshraghi et al. Correlation between Serum Lead Level and Coronary Slow Flow Phenomenon
Berkowitz et al. Management of the Hyperlipidemic Patient
Colhoun et al. Cholesterol lowering with atorvastatin for the primary prevention of cardiovascular disease in diabetic adults